Glaxo Who? Why Gilead's HIV Drug Could Be the 'Greatest of All Time'

Glaxo Who? Why Gilead's HIV Drug Could Be the 'Greatest of All Time'
- Young estimates that the drug could have peak sales of $4 billion in 2023, five years after the launch, which will help Gilaed overcome HIV products that are set to lose patent protection. She thinks that bictegravir can grow 45% on an annualized basis over the next 5 years. Gilead is up 1.3% in recent ...